Quick Takes in Clinical Research

Quantifying treatment effect: relative and absolute measures in clinical research

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 16 April 2026
0
Views
0
Downloads

Authors

Quantifying the effect of treatment is crucial for clinical decision-making. Effect measures can be expressed in absolute terms, such as risk difference, number needed to treat, or number needed to harm, or in relative terms, including risk ratio, odds ratio, and incidence rate ratio. Although all are derived from the same data, they provide different perspectives: relative measures capture proportional changes, while absolute measures translate these into clinically meaningful terms. Confidence intervals (CIs) are essential to assess the precision of these estimates and to evaluate their statistical significance and potential clinical relevance. In this methodological note, we illustrate the use of these measures with examples from studies on venous thromboembolism, a clinical field where both benefits and risks of anticoagulant therapy (i.e., thrombosis and bleeding) must be carefully balanced. Clinicians and researchers should be aware of the strengths and limitations of each measure. A balanced interpretation, integrating absolute and relative metrics together with their CIs, is central to properly assessing treatment effects and to support evidence-based decision-making.

Downloads

Download data is not yet available.

Citations

Bonaventura A, Buso R, Dentali F. The research question: a first, essential step in study design. Ital J Med 2026;20:2130.
Rothman KJ, Greenland S. Modern Epidemiology, third revised edition. Philadelphia, PA, USA: Lippincott Williams & Wilkins; 2008.
Tripepi G, Jager KJ, Dekker FW, et al. Measures of effect: relative risks, odds ratios, risk difference, and “number needed to treat”. Kidney Int 2007;72:789-91.
Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med 2019;380:711-9.
Simes J, Becattini C, Agnelli G, et al. Aspirin for the prevention of recurrent venous thromboembolism the INSPIRE collaboration. Circulation 2014;130:1062-71.
Lee AYY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-53.
Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2011;365:687-96.
Prins MH, Lensing AW, Bauersachs R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013;11:21.
Monreal M, Suárez C, Fajardo JAG, et al. Management of patients with acute venous thromboembolism: findings from the RIETE registry. Pathophysiol Haemost Thromb 2003;33:330-4.
Blom JW, Doggen CJM, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005;293:715-22.
Khorana AA, Soff GA, Kakkar AK, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med 2019;380:720-8.

How to Cite



Quantifying treatment effect: relative and absolute measures in clinical research. (2026). Italian Journal of Medicine. https://doi.org/10.4081/itjm.2026.2386